Antiviral effects of statins.

[1]  N. Kiaie,et al.  Effects of statins on the biological features of mesenchymal stem cells and therapeutic implications , 2020, Heart Failure Reviews.

[2]  M. Banach,et al.  Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications , 2019, Journal of clinical medicine.

[3]  Bradley W Ellis,et al.  HIV-Nef Protein Transfer to Endothelial Cells Requires Rac1 Activation and Leads to Endothelial Dysfunction: Implications for Statin Treatment in HIV Patients. , 2019, Circulation research.

[4]  Weiwei Liu,et al.  Lovastatin Inhibits HIV-1-Induced MHC-I Downregulation by Targeting Nef–AP-1 Complex Formation: A New Strategy to Boost Immune Eradication of HIV-1 Infected Cells , 2019, Front. Immunol..

[5]  T. Avni,et al.  Statins and outcomes of hospitalized patients with laboratory-confirmed 2017–2018 influenza , 2019, European Journal of Clinical Microbiology & Infectious Diseases.

[6]  Jeong-Ki Kim,et al.  Lipophilic statins inhibit Zika virus production in Vero cells , 2019, Scientific Reports.

[7]  C. Eggeling,et al.  HIV-1 Gag specifically restricts PI(4,5)P2 and cholesterol mobility in living cells creating a nanodomain platform for virus assembly , 2019, Science Advances.

[8]  Xiang Liu,et al.  Association between statin use and herpes zoster: systematic review and meta-analysis , 2019, BMJ Open.

[9]  R. Eckel,et al.  Statin Toxicity: Mechanistic Insights and Clinical Implications , 2019, Circulation research.

[10]  M. Sorror,et al.  Human Rhinovirus Infections in Hematopoietic Cell Transplant Recipients: Risk Score for Progression to Lower Respiratory Tract Infection , 2018, Biology of Blood and Marrow Transplantation.

[11]  P. Muntner,et al.  Trends in Utilization of Statin Therapy and Contraindicated Statin Use in HIV‐‐Infected Adults Treated With Antiretroviral Therapy From 2007 Through 2015 , 2018, Journal of the American Heart Association.

[12]  R. Zeiser.  Immune modulatory effects of statins , 2018, Immunology.

[13]  A. McElroy,et al.  Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing , 2018, mBio.

[14]  D. Francisci,et al.  Hepatitis C virus and proprotein convertase subtilisin/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism , 2017, Journal of cellular and molecular medicine.

[15]  B. Wiggins,et al.  Recommendations for Managing Drug–Drug Interactions with Statins and HIV Medications , 2017, American Journal of Cardiovascular Drugs.

[16]  M. Pencina,et al.  Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. , 2016, Atherosclerosis.

[17]  J. Fedačko,et al.  Pleiotropic effects of statins in the diseases of the liver. , 2016, World journal of gastroenterology.

[18]  A. Sahebkar,et al.  The impact of statin therapy on plasma levels of von Willebrand factor antigen , 2015, Thrombosis and Haemostasis.

[19]  L. Delang,et al.  The future of antivirals: broad-spectrum inhibitors , 2015, Current opinion in infectious diseases.

[20]  Cameron P. Simmons,et al.  Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  A. Sahebkar,et al.  Association between statin use and plasma D-dimer levels , 2015, Thrombosis and Haemostasis.

[22]  Shari S. Rogal,et al.  Effect of addition of statins to antiviral therapy in hepatitis C virus–infected persons: Results from ERCHIVES , 2015, Hepatology.

[23]  M. Banach,et al.  Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials. , 2015, Atherosclerosis.

[24]  A. Omar,et al.  Mechanisms of Action and Efficacy of Statins against Influenza , 2014, BioMed research international.

[25]  M. Tremblay,et al.  Selective Acquisition of Host-Derived ICAM-1 by HIV-1 Is a Matrix-Dependent Process , 2014, Journal of Virology.

[26]  M. Bukrinsky,et al.  New Clues to Understanding HIV Nonprogressors: Low Cholesterol Blocks HIV Trans Infection , 2014, mBio.

[27]  L. Delang,et al.  Are statins a viable option for the treatment of infections with the hepatitis C virus? , 2014, Antiviral research.

[28]  K. Chayama,et al.  Letter: pitavastatin supplementation of PEG‐IFN/ribavirin improves sustained virological response against HCV , 2014, Alimentary pharmacology & therapeutics.

[29]  Duncan Wu.  Hepatitis B virus reactivation associated with atorvastatin. , 2013, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[30]  Qianqian Zhu,et al.  Potential role for statins in the treatment of chronic HCV infection , 2013 .

[31]  B. Fontoura,et al.  Nuclear Imprisonment: Viral Strategies to Arrest Host mRNA Nuclear Export , 2013, Viruses.

[32]  Benoit Chauvin,et al.  Drug–Drug Interactions Between HMG-CoA Reductase Inhibitors (Statins) and Antiviral Protease Inhibitors , 2013, Clinical Pharmacokinetics.

[33]  E. Mortensen,et al.  Are statins beneficial for viral pneumonia? , 2013, European Respiratory Journal.

[34]  W. Sundquist,et al.  How HIV finds the door , 2012, Proceedings of the National Academy of Sciences.

[35]  D. Barnard,et al.  Effect of statin treatments on highly pathogenic avian influenza H5N1, seasonal and H1N1pdm09 virus infections in BALB/c mice. , 2012, Future virology.

[36]  Jung Weon Lee,et al.  Simvastatin suppresses RANTES-mediated neutrophilia in polyinosinic–polycytidylic acid-induced pneumonia , 2012, European Respiratory Journal.

[37]  Qiuhong Wang,et al.  The Effects of Simvastatin or Interferon-α on Infectivity of Human Norovirus Using a Gnotobiotic Pig Model for the Study of Antivirals , 2012, PloS one.

[38]  R. Wunderink,et al.  The Effect of Rosuvastatin in a Murine Model of Influenza A Infection , 2012, PloS one.

[39]  E. Wherry,et al.  A Role for the Chemokine RANTES in Regulating CD8 T Cell Responses during Chronic Viral Infection , 2011, PLoS pathogens.

[40]  M. Martínez-Gutiérrez,et al.  Statins Reduce Dengue Virus Production via Decreased Virion Assembly , 2011, Intervirology.

[41]  M. Azarpazhooh,et al.  Simvastatin Therapy Reduces Prooxidant-Antioxidant Balance: Results of a Placebo-Controlled Cross-Over Trial , 2011, Lipids.

[42]  F. Otsuka,et al.  Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling , 2010, Regulatory Peptides.

[43]  B. Korba,et al.  Simvastatin potentiates the anti-hepatitis B virus activity of FDA-approved nucleoside analogue inhibitors in vitro. , 2010, Antiviral research.

[44]  R. Chung,et al.  An identification of the novel combination therapy for hepatitis C virus 1b infection by using a replicon system and human induced pluripotent stem cells , 2010, Hepatology.

[45]  R. Chung,et al.  New translational research on novel drugs for hepatitis C virus 1b infection by using a replicon system and human induced pluripotent stem cells , 2010, Hepatology.

[46]  Tasleem Samji.  Influenza A: Understanding the Viral Life Cycle , 2009, The Yale journal of biology and medicine.

[47]  D. Redelmeier,et al.  Influenza Morbidity and Mortality in Elderly Patients Receiving Statins: A Cohort Study , 2009, PloS one.

[48]  K. Forde,et al.  Do statins reduce hepatitis C RNA titers during routine clinical use? , 2009, World journal of gastroenterology.

[49]  F. Zoulim,et al.  Statins potentiate the in vitro anti‐hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development , 2009, Hepatology.

[50]  S. Antinori,et al.  Does fluvastatin favour HCV replication in vivo? A pilot study on HIV–HCV coinfected patients , 2009, Journal of viral hepatitis.

[51]  M. Labow,et al.  Cholesterol biosynthesis modulation regulates dengue viral replication. , 2009, Virology.

[52]  C. Montoya,et al.  Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial , 2009, Trials.

[53]  L. Mascitelli,et al.  The double-edged sword of statin immunomodulation. , 2009, International journal of cardiology.

[54]  Li Wu,et al.  Intercellular Adhesion Molecule 1 (ICAM-1), but Not ICAM-2 and -3, Is Important for Dendritic Cell-Mediated Human Immunodeficiency Virus Type 1 Transmission , 2009, Journal of Virology.

[55]  T. Kinoshita,et al.  Association of dengue virus NS1 protein with lipid rafts. , 2008, The Journal of general virology.

[56]  C. Aston,et al.  Fluvastatin Inhibits Hepatitis C Replication in Humans , 2008, The American Journal of Gastroenterology.

[57]  B. Clotet,et al.  Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART. , 2007, The Journal of antimicrobial chemotherapy.

[58]  R. Parton,et al.  Cholesterol manipulation by West Nile virus perturbs the cellular immune response. , 2007, Cell host & microbe.

[59]  W. Paxton,et al.  Statins Disrupt CCR5 and RANTES Expression Levels in CD4+ T Lymphocytes In Vitro and Preferentially Decrease Infection of R5 Versus X4 HIV-1 , 2007, PloS one.

[60]  J. Chu,et al.  c-Src protein kinase inhibitors block assembly and maturation of dengue virus , 2007, Proceedings of the National Academy of Sciences.

[61]  M. Bukrinsky,et al.  Human Immunodeficiency Virus Impairs Reverse Cholesterol Transport from Macrophages , 2006, PLoS Biology.

[62]  D. Fedson.  Pandemic Influenza: A Potential Role for Statins in Treatment and Prophylaxis , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[63]  K. Naka,et al.  Different anti‐HCV profiles of statins and their potential for combination therapy with interferon , 2006, Hepatology.

[64]  M. Tremblay,et al.  Statins could be used to control replication of some viruses, including HIV-1. , 2005, Viral immunology.

[65]  M. Gale,et al.  Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. , 2005, Molecular cell.

[66]  C. Arana,et al.  VSV disrupts the Rae1/mrnp41 mRNA nuclear export pathway. , 2005, Molecular cell.

[67]  C. Martínez-A,et al.  Statins Inhibit HIV-1 Infection by Down-regulating Rho Activity , 2004, The Journal of experimental medicine.

[68]  P. Libby,et al.  Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents? , 2004, Circulation.

[69]  A. Branzi,et al.  Hydroxymethyl-Glutaryl Coenzyme A Reductase Inhibition Limits Cytomegalovirus Infection in Human Endothelial Cells , 2004, Circulation.

[70]  M. Tremblay,et al.  Presence of Host ICAM-1 in Human Immunodeficiency Virus Type 1 Virions Increases Productive Infection of CD4+ T Lymphocytes by Favoring Cytosolic Delivery of Viral Material , 2003, Journal of Virology.

[71]  D. Graham,et al.  Lipid rafts and HIV pathogenesis: virion-associated cholesterol is required for fusion and infection of susceptible cells. , 2003, AIDS research and human retroviruses.

[72]  S. Nir,et al.  Sphingomyelin and Cholesterol Promote HIV-1 gp41 Pretransmembrane Sequence Surface Aggregation and Membrane Restructuring* , 2002, The Journal of Biological Chemistry.

[73]  Dzung H. Nguyen,et al.  Lipid rafts and HIV pathogenesis: host membrane cholesterol is required for infection by HIV type 1. , 2001, AIDS research and human retroviruses.

[74]  B. Graham,et al.  Antiviral Activity of Lovastatin against Respiratory Syncytial Virus In Vivo and In Vitro , 2001, Antimicrobial Agents and Chemotherapy.

[75]  C. Martínez-A,et al.  Membrane raft microdomains mediate lateral assemblies required for HIV‐1 infection , 2000, EMBO reports.

[76]  A. Trkola,et al.  Co-receptors for HIV-1 entry. , 1997, Current opinion in immunology.

[77]  H. Shang,et al.  ICAM-1 in HIV infection and underlying mechanisms. , 2019, Cytokine.

[78]  J. Peiris,et al.  Immunomodulatory and anti-viral effects of statins in influenza H5N1 virus infection of human alveolar epithelial cells and peripheral blood–derived macrophages , 2013 .

[79]  W. Schaffner,et al.  Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: a multistate study. , 2012, The Journal of infectious diseases.

[80]  D. Schuppan,et al.  Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: a prospective randomized pilot study. , 2012, Journal of hepatology.

[81]  G. Rao,et al.  Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. , 2011, Gastroenterology.

[82]  C. Scarneciu,et al.  STATINS - A NEW OPTION FOR THE ANTIVIRAL TREATMENT? PRELIMINARY STUDY , 2009 .

[83]  P. Kuna,et al.  Chemokines in seasonal allergic rhinitis. , 1996, The Journal of allergy and clinical immunology.